No Data
LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $50
Strong Financial Position and Promising Clinical Developments Position Spyre Therapeutics for Success
Wedbush Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $65
BTIG Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $70
Spyre Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q1 EPS Results.
TD Cowen Maintains Spyre Therapeutics(SYRE.US) With Buy Rating
